Loading clinical trials...

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of MM-093 in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT00147329•Merrimack Pharmaceuticals

View on ClinicalTrials.gov

Summary

Merrimack is conducting a research study to see if an experimental drug, called MM-093, is safe and effective in the treatment of psoriasis. MM-093 is a genetically engineered version of a naturally occurring protein called alpha fetoprotein (AFP). Adults normally have very small amounts of AFP in their bloodstream. However, during pregnancy, AFP levels in both the mother and the fetus are much higher than normal. It has been observed that some women with psoriasis and other autoimmune diseases such as rheumatoid arthritis have fewer symptoms during pregnancy, particularly during the third trimester. At this time, the levels of AFP in the blood of the mother and fetus are the highest. This observation led Merrimack to begin examining MM-093 as a potential treatment for psoriasis. This study is designed to further test the safety and effectiveness of MM-093 in patients with psoriasis.

Detailed Description

TBA

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Aged 18 years and above.
•Understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures being performed.
•Have had active plaque psoriasis for at least 6 months.
•Had disease onset at \<40 years of age.
•Have had stable disease, as judged by the investigator, for at least 2 months prior to screening.
•Have moderate-to-severe psoriasis that is unresponsive to, or inappropriate for treatment with, topical therapy only.
•Have moderate-to-severe chronic plaque psoriasis as defined by each of the following:
•Have at least 10% of their body covered by disease, AND
•Have a PGA score ≥3, AND
•Have 3 or more lesions that are greater than 2 cm and are easily measured and acceptable for biopsy and photographs.
+31 more criteria

Locations (2)

Texas Dermatology Research Institute

Dallas, Texas, United States

U. of Utah School of Medicine- Department of Dermatology

Salt Lake City, Utah, United States

Key Dates

Start Date

September 1, 2005

Completion Date

July 1, 2006

Last Updated

February 23, 2007

Enrollment

Estimated participants

Conditions

Psoriasis

Interventions

MM-093

DRUG

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 23, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

Inclusion Criteria

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments